"Suchop\u00E1r, Josef" . . . "CZ - \u010Cesk\u00E1 republika" . . "Remedia" . . "2"^^ . "1"^^ . . "Bultas, Jan" . . . . . "Angiotensin converting enzyme inhibitors and angiotensin II AT1 receptor antagonists (sartans) used in the secondary prevention of cardiovascular events, comparison of basic data"@en . "RIV/00216208:11120/10:00002678" . . "Inhibitory ACE a antagonist\u00E9 receptor\u016F AT1 pro angiotenzin II (sartany) vyu\u017Eiteln\u00E9 v r\u00E1mci sekund\u00E1rn\u00ED prevence kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, porovn\u00E1n\u00ED z\u00E1kladn\u00EDch \u00FAdaj\u016F"@cs . "\u010Cl\u00E1nek shrnuje nejv\u00FDznamn\u011Bj\u0161\u00ED farmakologick\u00E1 a klinick\u00E1 data t\u00FDkaj\u00EDc\u00ED se l\u00E9\u010Div ovliv\u0148uj\u00EDc\u00EDch syst\u00E9m renin-angiotenzin-aldosteron, kter\u00E1 lze pou\u017E\u00EDt p\u0159i sekund\u00E1rn\u00ED prevenci kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod. P\u0159\u00EDzniv\u00FD vliv na progn\u00F3zu nemocn\u00FDch byl prok\u00E1z\u00E1n velk\u00FDmi randomizovan\u00FDmi studiemi u ramiprilu, perindoprilu, trandolaprilu a telmisartanu." . "Inhibitory ACE a antagonist\u00E9 receptor\u016F AT1 pro angiotenzin II (sartany) vyu\u017Eiteln\u00E9 v r\u00E1mci sekund\u00E1rn\u00ED prevence kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, porovn\u00E1n\u00ED z\u00E1kladn\u00EDch \u00FAdaj\u016F" . "11120" . . "Inhibitory ACE a antagonist\u00E9 receptor\u016F AT1 pro angiotenzin II (sartany) vyu\u017Eiteln\u00E9 v r\u00E1mci sekund\u00E1rn\u00ED prevence kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, porovn\u00E1n\u00ED z\u00E1kladn\u00EDch \u00FAdaj\u016F" . "RIV/00216208:11120/10:00002678!RIV11-MSM-11120___" . "secondary prevention; cardiovascular events; renin-angiotensin-aldosterone system; ramipril; perindopril; trandolapril"@en . "V" . "20" . . "2" . . "7"^^ . . "[611A1274742A]" . . "0862-8947" . . "264011" . "Angiotensin converting enzyme inhibitors and angiotensin II AT1 receptor antagonists (sartans) used in the secondary prevention of cardiovascular events, comparison of basic data"@en . "Inhibitory ACE a antagonist\u00E9 receptor\u016F AT1 pro angiotenzin II (sartany) vyu\u017Eiteln\u00E9 v r\u00E1mci sekund\u00E1rn\u00ED prevence kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, porovn\u00E1n\u00ED z\u00E1kladn\u00EDch \u00FAdaj\u016F"@cs . . "\u010Cl\u00E1nek shrnuje nejv\u00FDznamn\u011Bj\u0161\u00ED farmakologick\u00E1 a klinick\u00E1 data t\u00FDkaj\u00EDc\u00ED se l\u00E9\u010Div ovliv\u0148uj\u00EDc\u00EDch syst\u00E9m renin-angiotenzin-aldosteron, kter\u00E1 lze pou\u017E\u00EDt p\u0159i sekund\u00E1rn\u00ED prevenci kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod. P\u0159\u00EDzniv\u00FD vliv na progn\u00F3zu nemocn\u00FDch byl prok\u00E1z\u00E1n velk\u00FDmi randomizovan\u00FDmi studiemi u ramiprilu, perindoprilu, trandolaprilu a telmisartanu."@cs . "The review summarizes the most important pharmacological characteristics and clinical data of renin-angiotensin-aldosterone system blockers, which can be used in the secondary prevention of cardiovascular events. Positive influence on the prognosis of patients has been demonstrated in large randomized studies with ramipril, perindopril, trandolapril, and telmisartan."@en .